Phase 1 Osteoarthritis Trial, Recruiting NCT06748651 Sponsor: Dr. Amit Druyan Condition: Osteoarthritis
Back to Osteoarthritis

Phase 1 Osteoarthritis Trial, Recruiting

NCT06748651
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with osteoarthritis of the jaw joint (the temporomandibular joint, or TMJ) on the side being treated.
  • People whose jaw joint MRI scan shows signs of inflammation.
  • People whose blood test results (checking general health, salt levels, and kidney and liver function) are within an acceptable range.

Who may not be able to join:

  • People who have had an injection directly into the jaw joint being treated within the past 3 months.
  • People who have had a significant injury or surgery to the jaw joint being treated.
  • People with signs of an active infection near the jaw joint being treated, or a significant active infection anywhere else in the body.
  • People with a known neurological (nervous system) disease, a rheumatic condition, a major health condition that could affect quality of life and influence the study results, or unexplained pain from an unknown cause.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 972-3-5304413

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Dr. Amit Druyan
Registry
ClinicalTrials.gov
Start date
15 December 2024
Est. completion
7 February 2026

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Number and severity of AEs, SAEs and injection reactions following treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov